Loading articles…
Loading articles…
Research included in this condition report
3 rights-cleared articles published in 2016, ordered newest first.
3 articles from 2016
Newest firstCannabidiol (CBD) is a major Cannabis sativa constituent, which does not cause the typical marijuana psychoactivity. However, it has been shown to be active in a numerous pharmacological assays, including mice tests for anxiety, obsessive-compulsive disorder, depression and schizophrenia. In human trials the doses of CBD needed to achieve effects in anxiety and schizophrenia are high. We report now the synthesis o…
Converging evidence suggests that an imbalance of ω3 to ω6 polyunsaturated fatty acid (PUFA) in the brain is involved in mental illnesses such as anxiety disorders. However, the underlying mechanism is unknown. We previously reported that the dietary ratio of ω3 to ω6 PUFA alters this ratio in the brain, and influences contextual fear memory. In addition to behavioral change, enhancement of cannabinoid CB1 recepto…
OBJECTIVES: Cannabis is now the most widely used illicit substance in the world. Previous research demonstrates that cannabis use is associated with dysfunctional affect regulation and anxiety. Anxiety is characterised by attentional biases in the presence of emotional information. This novel study therefore examined the attentional bias of cannabis users when presented with anxiety-related stimuli. The aim was to…